Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Interest & Investment Income: 2022-2025

Historic Interest & Investment Income for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $3.6 million.

  • Entrada Therapeutics' Interest & Investment Income fell 38.07% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year decrease of 8.45%. This contributed to the annual value of $19.5 million for FY2024, which is 27.97% up from last year.
  • Entrada Therapeutics' Interest & Investment Income amounted to $3.6 million in Q3 2025, which was down 9.00% from $3.9 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Interest & Investment Income peaked at $5.8 million during Q3 2024, and registered a low of $403,000 during Q2 2022.
  • Over the past 3 years, Entrada Therapeutics' median Interest & Investment Income value was $4.2 million (recorded in 2023), while the average stood at $4.2 million.
  • Per our database at Business Quant, Entrada Therapeutics' Interest & Investment Income surged by 946.65% in 2023 and then tumbled by 38.07% in 2025.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Interest & Investment Income stood at $950,000 in 2022, then soared by 351.79% to $4.3 million in 2023, then rose by 19.48% to $5.1 million in 2024, then slumped by 38.07% to $3.6 million in 2025.
  • Its Interest & Investment Income stands at $3.6 million for Q3 2025, versus $3.9 million for Q2 2025 and $4.4 million for Q1 2025.